<DOC>
	<DOCNO>NCT01436968</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ProstAtak® immunotherapy combination radiation therapy patient intermediate-high risk localize prostate cancer . ProstAtak kill tumor cell stimulate cancer vaccine effect . Killing tumor cell immune stimulatory environment induces body 's immune system detect destroy cancer cell . ProstAtak show synergy radiation without added toxicity lower expect recurrence rate previous clinical trial . The hypothesis ProstAtak lead improvement clinical outcome patient prostate cancer . Participants randomize ProstAtak control arm 2:1 ratio . Both arm receive standard external beam radiation therapy . Short-term androgen deprivation therapy may give require .</brief_summary>
	<brief_title>Phase 3 Study ProstAtak® Immunotherapy With Standard Radiation Therapy Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria include : Localized prostate cancer meeting NCCN criterion Intermediate Risk patient one NCCN highrisk feature NCCN Intermediate Risk define least one following : PSA 1020 ng/ml , Gleason score =7 , T2bT2c High Risk single high risk feature define one following : PSA &gt; 20 ng/ml , Gleason score 810 , T3a Excluded follow risk group : Low risk ; High risk 1 high risk factor ; Locally advanced/very high risk=T3bT4 ; Metastatic : N1 M1 Planning undergo standard prostateonly external beam radiation therapy ECOG Performance Status 02 Exclusion Criteria include : Liver disease , include know cirrhosis active hepatitis Patients systemic corticosteroid ( &gt; 10mg prednisone per day ) immunosuppressive drug Known HIV+ patient Regional lymph node involvement distant metastases Patients plan receive whole pelvic irradiation Prior treatment prostate cancer , except TURP ADT . For ADT , may give maximum 6 month Patients plan orchiectomy form hormonal ablation Known sensitivity allergic reaction acyclovir valacyclovir</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>immunotherapy , cytotoxicity , tumor vaccine , prostate cancer , radiotherapy</keyword>
</DOC>